One potential difficultly here is that good metrics are hard, and outcomes for a lot of medicine are hard to evaluate. Obviously not true everywhere.
So a potential path will be that the incentives start to line up with measurable impact on symptoms short term (easy outcome to evaluate) instead of meaningful shift in root causes (difficult and/or slow to measure)
So a potential path will be that the incentives start to line up with measurable impact on symptoms short term (easy outcome to evaluate) instead of meaningful shift in root causes (difficult and/or slow to measure)